3SBio Inc. (SSRX)
-NasdaqGS 16.58 
0.02(0.12%) 4:00PM EDT
| Prev Close: | 16.56 |
|---|
| Open: | 16.59 |
|---|
| Bid: | 16.12 x 200 |
|---|
| Ask: | 16.64 x 1000 |
|---|
| 1y Target Est: | 17.90 |
|---|
| Beta: | 1.05 |
|---|
| Next Earnings Date: | 24-May-13 |
|---|
| Day's Range: | 16.53 - 16.64 |
|---|
| 52wk Range: | 10.15 - 16.70 |
|---|
| Volume: | 64,172 |
|---|
| Avg Vol (3m): | 158,973 |
|---|
| Market Cap: | 390.96M |
|---|
| P/E (ttm): | 23.22 |
|---|
| EPS (ttm): | 0.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- China Biotech In Review: Chindex Buys Israeli Laser Company For $240 Millionat Seeking Alpha(Sun, May 5)
- 3SBIO INC. FinancialsEDGAR Online Financials(Sat, May 4)
- 3SBio Inc. Announces Extraordinary General Meeting of ShareholdersPR Newswire(Thu, May 2)
- In Development-Stage Biotechs, Success Comes Down to One Asset: Expert Analyst Boris Peaker Discusses the Competitive Biotechnology Environment with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
- 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012PR Newswire(Wed, May 1)
- Asia Private Equity Weekly News, April 29, 2013at Reuters(Sun, Apr 28)
- China Biotech In Review: WuXi PharmaTech Contributes To Syros Pharma Fundingat Seeking Alpha(Sun, Apr 28)
- 3SBio Inc. Adjourns Extraordinary General Meeting of ShareholdersPR Newswire(Thu, Apr 25)
- 3SBio Inc. Enters Into Amendment to Merger Agreement For "Going Private" TransactionPR Newswire(Wed, Apr 24)
- UPDATE 1-Consortium raises offer for China's 3SBioat Reuters(Mon, Apr 22)
- Consortium raises offer for 3SBioat Reuters(Mon, Apr 22)
- 3SBio Inc. Announces Receipt of Amended "Going Private" Proposal at $16.70 Per ADS and Intent to Adjourn Extraordinary General Meeting of ShareholdersPR Newswire(Mon, Apr 22)
- Opposition to 3SBio's Buyout Grows Ahead of Deal Voteat The Wall Street Journal(Fri, Apr 19)
- OrbiMed Advisors Announces Institutional Shareholder Services Recommendation that 3SBio Shareholders Vote AGAINST Management Buyout ProposalBusiness Wire(Mon, Apr 15)
- Glass Lewis Recommends 3SBio Shareholders Vote against Management Buyout ProposalBusiness Wire(Fri, Apr 12)
Key Statistics
| Forward P/E (1 yr): | 14.80 |
|---|
| P/S (ttm): | 3.65 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.92 |
|---|
| Quarterly EPS Est
(Mar-13)
: | 0.18 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.39 |
|---|
Business Summary
3SBio Inc., a biotechnology company, engages in the research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the producti...
View More